<DOC>
	<DOCNO>NCT00086502</DOCNO>
	<brief_summary>The purpose study determine safety efficacy investigational drug patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Pioglitazone Add-on Study Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Patient type 2 diabetes mellitus ( T2DM ) Patient 18 year age ( old ) Patient pregnant breastfeeding plan become pregnant duration study poststudy followup period Patient history type 1 diabetes mellitus history ketoacidosis Patient require insulin within prior 8 week Patient weight loss program maintenance phase Patient start weight loss medication ( e.g. , orlistat sibutramine ) within prior 8 week Patient likely require treatment treatment immunosuppressive agent ( e.g. , cyclosporin , methotrexate ) Patient cirrhosis , active liver disease ( fatty liver ) symptomatic gallbladder disease Patient chronic myopathy , progressive neurological neuromuscular disorder ( e.g. , multiple sclerosis polymyositis ) Patient follow disorder within past 6 month : Acute coronary syndrome ( e.g. , MI unstable angina ) , Coronary artery intervention , Stroke transient ischemic neurological disorder . Patient new worsen sign symptom coronary heart disease within past 3 month Patient severe peripheral vascular disease Patient congestive heart failure Patient HIV positive Patient clinically important hematological disorder ( e.g. , aplastic anemia , myeloproliferative myelodysplastic syndrome , thrombocytopenia ) Patient history neoplastic disease Patient history alcohol drug abuse within past 3 year Patient viral hepatitis ( hepatitis B C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>